MX362848B - Derivado de xantina. - Google Patents

Derivado de xantina.

Info

Publication number
MX362848B
MX362848B MX2015000159A MX2015000159A MX362848B MX 362848 B MX362848 B MX 362848B MX 2015000159 A MX2015000159 A MX 2015000159A MX 2015000159 A MX2015000159 A MX 2015000159A MX 362848 B MX362848 B MX 362848B
Authority
MX
Mexico
Prior art keywords
pharmaceutically acceptable
acceptable salts
xanthine derivative
medicines
experiments
Prior art date
Application number
MX2015000159A
Other languages
English (en)
Other versions
MX2015000159A (es
Inventor
Ying Wang
Yongzhe Xiang
Guodong Cen
Jian Liu
Ning Zhou
Jibing Zhang
Long Huang
Original Assignee
Chengdu Easton Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Easton Biopharmaceuticals Co Ltd filed Critical Chengdu Easton Biopharmaceuticals Co Ltd
Publication of MX2015000159A publication Critical patent/MX2015000159A/es
Publication of MX362848B publication Critical patent/MX362848B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención divulga un derivado de xantina que tiene la estructura de la siguiente formula general (I) o una sal farmacéuticamente aceptable de la misma; además divulga un método de preparación para el derivado de xantina o una sal farmacéuticamente aceptable del mismo; y además divulga el uso del derivado de xantina o una sal farmacéuticamente aceptable del mismo. A través de los experimentos de DPP-IV actividad de inhibición experimentos in Vitro, el impacto de tolerancia de glucosa en ratones normales y el impacto de glucosa en sangre en los ratones diabéticos espontáneos, prueba que los compuestos y las sales farmacéuticamente aceptables de los mismos muestran una buena actividad de inhibición del DPP-IV, se puede aplicar para preparar medicinas para el tratamiento de enfermedades para el tratamiento de enfermedades relacionadas con dipeptidil peptidasa IV, y más particularmente, se puede aplicar al uso de medicamentos para el tratamiento de diabetes tipo II o enfermedades de tolerancia anormal a la glucosa.
MX2015000159A 2012-06-20 2013-05-15 Derivado de xantina. MX362848B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210205678.4A CN103509023B (zh) 2012-06-20 2012-06-20 黄嘌呤衍生物
PCT/CN2013/075627 WO2013189219A1 (zh) 2012-06-20 2013-05-15 黄嘌呤衍生物

Publications (2)

Publication Number Publication Date
MX2015000159A MX2015000159A (es) 2015-08-06
MX362848B true MX362848B (es) 2019-02-19

Family

ID=49768089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000159A MX362848B (es) 2012-06-20 2013-05-15 Derivado de xantina.

Country Status (9)

Country Link
US (1) US9255098B2 (es)
EP (1) EP2865680B1 (es)
JP (1) JP6080324B2 (es)
CN (1) CN103509023B (es)
AU (1) AU2013280099B2 (es)
CA (1) CA2879850C (es)
MX (1) MX362848B (es)
RU (1) RU2635109C2 (es)
WO (1) WO2013189219A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103936738B (zh) * 2013-01-23 2016-11-23 成都苑东生物制药股份有限公司 黄嘌呤衍生物
CN104292228B (zh) * 2013-07-16 2016-03-30 成都苑东生物制药股份有限公司 一种黄嘌呤化合物的多晶型及其制备方法、用途
WO2021109970A1 (zh) * 2019-12-02 2021-06-10 成都苑东生物制药股份有限公司 一种黄嘌呤衍生物药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
IL153182A0 (en) * 2000-07-04 2003-06-24 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
EP1953162B9 (de) 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
BR122012026540B8 (pt) * 2002-08-21 2021-05-25 Boehringer Ingelheim Pharma 8-[3-amino-piperidin-1-il]-xantinas, seus sais farmacêuticamente aceitáveis, seu uso e seu processo de preparação, bem como medicamento e seu processo de preparação
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
DE102004038268A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
JP6080324B2 (ja) 2017-02-15
WO2013189219A1 (zh) 2013-12-27
EP2865680A1 (en) 2015-04-29
AU2013280099A1 (en) 2015-01-22
JP2015521605A (ja) 2015-07-30
CA2879850A1 (en) 2013-12-27
MX2015000159A (es) 2015-08-06
US9255098B2 (en) 2016-02-09
CN103509023A (zh) 2014-01-15
RU2635109C2 (ru) 2017-11-09
AU2013280099B2 (en) 2017-02-16
CA2879850C (en) 2018-09-11
EP2865680A4 (en) 2015-11-25
CN103509023B (zh) 2014-08-27
RU2015101339A (ru) 2016-08-10
US20150183788A1 (en) 2015-07-02
EP2865680B1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
IN2014DN09782A (es)
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
PE20151727A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c
NZ603319A (en) Diabetes therapy
BR112014003198A2 (pt) compostos para o tratamento e profilaxia de doença por vírus sincicial respiratório
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
EA030383B9 (ru) Бициклически замещённые урацилы, способы их получения, их применение, лекарственное средство и способ лечения с их применением
NZ599298A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
PH12015500434A1 (en) Combination of sglt2 inhibitors and anti-hypertensive drugs
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX362848B (es) Derivado de xantina.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX348412B (es) Métodos de usar sns-595 para el tratamiento de sujetos con cáncer con actividad reducida de brca2.
NZ703549A (en) Benzodioxole derivative and preparation method and use thereof
PH12014501646A1 (en) Substituted phenylazole derivative
MX2022009874A (es) Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4).
BR112015005935A2 (pt) novos compostos inibidores de fosfodiesterase de tipo 10a
MY182801A (en) Compound for activating ampk and uses thereof
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: SURFACE SPECIALTIES, S.A.

FG Grant or registration